TLI in refractory chronic GVHD

R. Devillier, L. Castagna, L. Gonzague, J. El-Cheikh, S. Fürst, C. Faucher, R. Michel, D. Blaise

Research output: Contribution to journalArticlepeer-review


Refractory chronic GVHD (cGVHD) remains a major cause of morbidity after transplantation. Many drugs are used but there is no consensus on the standard of care. We investigated the efficacy of TLI in corticosteroid-refractory cGVHD. We analyzed retrospectively 31 patients receiving one or more TLI session for refractory cGVHD from 2000 to 2007. The main objective was to evaluate the response rate after TLI. Decreased corticosteroid doses and/or discontinued immunosuppressive agents were considered to be surrogate markers of response. All but one patient presented with severe cGVHD at the time of TLI. The median number of previous immunosuppressive treatment lines was 3 (range: 2-4). Fourteen patients (45%) achieved an objective response after TLI and 8 (25%) were cGVHD free at long-term follow-up. In all, 5 (29%) of the 17 nonresponsive patients did not show the features of progressive cGVHD and could decrease the amount of immunosuppressive drugs taken. Response after TLI significantly improved 5-year GVHD-related mortality (14% vs 42%, P=0.038) but not OS (58%vs 64% P=0.27). Regarding the promising response rate in this heavily pretreated population, we reasoned that TLI could be an alternative treatment for corticosteroid-refractory cGVHD.

Original languageEnglish
Pages (from-to)854-858
Number of pages5
JournalBone Marrow Transplantation
Issue number6
Publication statusPublished - Jun 2013


  • chronic GVHD
  • immunosuppressive treatment
  • TLI

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'TLI in refractory chronic GVHD'. Together they form a unique fingerprint.

Cite this